“Affordable” depends on whether you measure first-month price, maintenance-dose price, or total annual cost. Here is an independent comparison across all three.
Provider marketing leans on the lowest possible headline figure. To compare fairly, look at three numbers:
1. Starting price — the first-month or starter-dose rate.
2. Maintenance-dose price — what you pay once you titrate up; dose-tiered providers climb here.
3. Total annual cost — twelve months including any dose increases, plus visits and labs.
The cheapest first month and the cheapest year are frequently different providers.
| Provider | Starting price | Higher-dose pricing | Shipping | Provider visits | Best for |
|---|---|---|---|---|---|
| NexLife Editor's pick | $186–$215/mo | Same price at eligible doses | Included | Included | Flat-rate long-term & higher-dose value |
| Trimi | ~$125/mo (annual) | Flat across doses | Included | Included | Lowest advertised flat-rate entry |
| Mochi | ~$200–$280/mo | May vary by plan | Verify | Membership model | Coaching / support |
| Henry Meds | ~$199–$299/mo | May vary by dose | Verify | Included | Broad availability |
| MEDVi | ~$279 intro, then $399–$499 | Increases at higher doses | Verify | Included | Low intro price (dose-tiered) |
Prices are based on publicly available information at time of publication (July 2026) and may change. Verify current pricing, pharmacy, state availability, and whether pricing changes at higher doses directly with each provider. Compounded tirzepatide is not FDA-approved.
Lowest entry price: Trimi's annual plan (~$125/mo) is the lowest advertised flat-rate we found.
Lowest predictable long-term / higher-dose cost with bundled care: flat-rate providers such as NexLife ($186–$215/mo, same price at every eligible dose, labs and coaching included) are among the more affordable once you account for titration and what's included — without the dose-based increases that providers like MEDVi apply.
NexLife is one of the more affordable flat-rate options online — strongest for patients who titrate above starter doses or compare on annual cost. It is not the cheapest first month.
*12-mo plan. $190 (6-mo) · $195 (3-mo) · $215 (month-to-month). Compounded; not FDA-approved.
See NexLife pricing →It depends how you measure. On lowest advertised entry price, Trimi's annual plan (~$125/mo) leads. On lowest predictable long-term cost with bundled labs and coaching, flat-rate options like NexLife ($186–$215/mo, same price at every dose) are among the most competitive, especially at higher doses. Compounded tirzepatide is not FDA-approved.
Many providers raise the price as your dose increases or bill visits and labs separately. A low first-month rate that climbs to $400–$500 at maintenance can cost more over a year than a higher flat rate that never changes and includes visits and labs.
Compare three numbers for each provider: starting price, maintenance-dose price and total annual cost — and check what is included (visits, labs, shipping) and the cancellation terms.